The DOI matches its Crossref record; 203 of the 205 references it cites were found in a registry or an index.
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel: This paper is also published in parallel in Archives of Medical Science [Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11(1): 1–23]
Open accessAbstract
Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Self-citation2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management
Authors Task Force Members, Kristensen, S. D., Knuuti, J., Saraste, A., Anker, S. D., Bøtker, H. E., Hert, S. D., Ford, I., González‐Juanatey, J. R., Görenek, B., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu282 · Cited by 1,698
Self-citationThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Research works printed but not linked: 14
- Banach M, 2009, Med Sci Monit, 15, MS1
- Colantonio LD, 2014, J Am Soc Nephrol
- Stroes ES, 2015, Eur Heart J
- 10.1016/S0025-6196(11)60897-5 · DOI
- 10.1016/j.taap.2012.01.008 · DOI · Paper page
- Gaitonde DY, 2012, Am Fam Physician, 86, 244
- Farias Moeller R, 2011, Case Rep Pediatr, 2011, 670673
- Bar SL, 2007, Can Fam Physician, 53, 428
- Balmer ML, 2008, Swiss Med Wkly, 138, 415
- Rysz J, 2006, Cell Mol Immunol, 3, 151
- Martin SS, 2013, Tresch and Aronow’s cardiovascular disease in the elderly, 121
- Banach M, 2015, Pharmacol Res
- Vandiver W, 2013, Fam Pract, 62, 730
- Adcock B, 2001, J Am Board Fam Pract, 14, 148
Cited by
Sorted by citations
Items 101–162 of 162
CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia
Siddiqui, M. K., Veluchamy, A., Maroteau, C., Tavendale, R., Carr, F., Pearson, E. R., Colhoun, H. M., Morris, A. D., Casella, G., Doney, A. S. F., et al. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001737 · Cited by 7
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 7
Amante, C., Esposito, T., Luccheo, G., Luccheo, L., Russo, P., & Gaudio, P. D. (2022) · Life · doi:10.3390/life12081162 · Cited by 7
Role of bempedoic acid in patients with hypercholesterolemia and statin intolerance
Girardi, J. M., & do Couto, A. A. (2023) · Journal Archives of Health · doi:10.46919/archv4n1-011 · Cited by 7
Hubacek, J. A., Adámková, V., Zlatohlávek, L., Mrazova, L. S., & Vrablı́k, M. (2017) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2017-0027 · Cited by 6
Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres
Wierzbicki, A. S., Viljoen, A., Viljoen, S., Martin, S. C., Crook, M. A., & Reynolds, T. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13242 · Cited by 6
Bempedoic acid for the treatment of hypercholesterolemia
Yang, J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1782744 · Cited by 6
Wasim, R., Mahmood, T., Shamim, A., Ahsan, F., & Singh, A. (2023) · Intelligent Pharmacy · doi:10.1016/j.ipha.2023.08.011 · Cited by 8
PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders
Grygiel‐Górniak, B., Ziółkowska‐Suchanek, I., Kaczmarek, E., Mosor, M., Nowak, J., & Puszczewicz, M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s157186 · Cited by 6
Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations
Orringer, C. E., Tokgözoğlu, L. S., Maki, K. C., Ray, K. K., Saseen, J. J., & Catapano, A. L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018189 · Cited by 7
Self-citationSun, G., & Liang, X. (2023) · Journal of Health Population and Nutrition · doi:10.1186/s41043-023-00482-3 · Cited by 5
Cho, K., Bahuguna, A., Kim, J. E., & Lee, S. (2024) · Pharmaceuticals · doi:10.3390/ph17060714 · Cited by 5
An update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease
Toth, P. P. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1356 · Cited by 5
Self-citationStreja, E., Streja, D. A., Soohoo, M., Kleine, C., Hsiung, J., Park, C., & Moradi, H. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.05.007 · Cited by 5
The effect of statins intake on sleep quality
Trambowicz, K., Staciwa, M., Broncel, M., & Gorzelak‐Pabiś, P. (2023) · Journal of Health Inequalities · doi:10.5114/jhi.2023.131805 · Cited by 4
Self-citationEfficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases
Commins, I., Clayton‐Chubb, D., Janko, N., Majeed, A., Kemp, W. W., & Roberts, S. K. (2026) · Medical Sciences · doi:10.3390/medsci14010084 · Cited by 4
Safe use of statins: focus on muscle toxicity
Kolovou, V., Bilianou, H. I., & Kolovou, G. D. (2016) · Clinical Lipidology · doi:10.1080/17584299.2016.1239873 · Cited by 5
The Role of Statins in Cirrhosis
Moctezuma‐Velázquez, C., & Abraldeṣ, J. G. (2022) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-022-00394-x · Cited by 4
Choi, J., Park, S., & Kim, S. (2024) · eFood · doi:10.1002/efd2.70020 · Cited by 4
Abordagem aos Doentes com Intolerância às Estatinas: Revisão Baseada na Evidência
Almeida, J. T., Esteves, A. L., Martins, F., & Palma, I. (2020) · Acta Médica Portuguesa · doi:10.20344/amp.10376 · Cited by 4
Personalized rosuvastatin therapy in problem patients with partial statin intolerance
Shek, A. B., Kurbanov, R. D., Alieva, R. B., Abdullaeva, G. J., Nagay, A. V., Abdullaev, A. A., Hoshimov, S. U., & Nizamov, U. I. (2018) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2018.76826 · Cited by 4
More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial)
Katsiki, N., Athyros, V. G., & Mikhailidis, D. P. (2016) · HORMONES · doi:10.14310/horm.2002.1658 · Cited by 4
Self-citationModifiable statin characteristics associated with potential statin‐related prescribing cascades
Wang, G. H., Morris, E. J., Vouri, S. M., Keshwani, S., Schmidt, S., Pepine, C. J., & Smith, S. M. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2883 · Cited by 3
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 3
Cho, K., Bahuguna, A., Kim, J. E., Lee, S., Lee, Y., & Jeon, C. (2025) · Pharmaceuticals · doi:10.3390/ph18020200 · Cited by 3
Significance of Statin-Associated Muscle Symptoms and Its Impact on Patients Adherence and Outcomes
Al-Makhamreh, H. K., Toubasi, A. A., Obaid, Y. Y., & Albustanji, F. H. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001386 · Cited by 4
Palomäki, A., Hällberg, V., Ala‐Korpela, M., Kovanen, P. T., & Malminiemi, K. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0292-6 · Cited by 3
Je, I., Park, J.-T., Lee, H. J., Im, A., Lee, J., & Kim, K.-Y. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128387531250713164724 · Cited by 2
Visual Disturbances Associated With Statins: A Case Report and Literature Review
Atapour, A., Panahishokouh, M., & Momenzadeh, M. (2025) · Clinical Medicine Insights Case Reports · doi:10.1177/11795476251400972 · Cited by 2
Mesenchymal Stem Cell Based-Regenerative Therapy in Atherosclerosis: an Updated Review
Mahaki, H., Sheykhhasan, M., Rahimi, H. R., Kazemzadeh, G., Ravari, H., Nobari, S., Izadi, H. S., Darroudi, S., Forouzanfar, F., Afkhami, H., et al. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02332-6 · Cited by 2
de Beer, R., Outhoff, K., Phulukdaree, A., & Soma, P. (2021) · Xenobiotica · doi:10.1080/00498254.2021.1945165 · Cited by 2
Louro, R., Melo, R. G. E., Ruivo, J., Almeida, A. G., Pinto, F. J., & Caldeira, D. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2274502 · Cited by 3
Abdelazim, A. M., Ismail, T. A., Abomughaid, M. M., & Saadaldin, I. M. (2021) · BioMed Research International · doi:10.1155/2021/6687551 · Cited by 2
Management of Statin Intolerance
Bartłomiejczyk, M. A., Penson, P. E., & Banach, M. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_12 · Cited by 1
Self-citationDeng, G., Kong, Q., Zhang, M., & Qi, L. (2025) · Journal of Visualized Experiments · doi:10.3791/69357 · Cited by 1
Objawy mięśniowe w przebiegu stosowania statyn — fakty, mity, rzeczywistość i stanowiska ekspertów
Starzyk, K., & Wożakowska−Kapłon, B. (2015) · Folia Cardiologica · doi:10.5603/fc.2015.0059 · Cited by 1
Katsiki, N., Sahebkar, A., & Banach, M. (2016) · Clinical Lipidology · doi:10.1080/17584299.2016.1243651 · Cited by 1
Self-citationStatins in real clinical practice: current guidelines, possibilities of new schemes for their use
Sargsyan, V. D., Kamyshova, T. V., Safaryan, A. S., Ахмеджанов, Н. М., Небиеридзе, Д. В., & Александровна, П. Е. (2019) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20192203186 · Cited by 1
Всеволодович, М. А., Borisovskaya, S. V., Гаврилина, Н. С., Игоревна, Г. И., Nikitin, I. G., & Александровна, Э. О. (2025) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2025-3110 · Cited by 1
Manejo de la intolerancia a estatinas: un desafío cotidiano en la práctica clínica
Miranda, N. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.25 · Cited by 1
Frequency of Rhabdomyolysis in Patients Treated with Statins in Hamad General Hospital, Qatar
Yousif, A.-M. B., Hassan, E. A., Ahmed, M. U., Lashin, M. S., Kunjumon, N. M., Sulaiman, T. O., Saliba, M., Shier, A. A., Babikir, M. M., Saeed, W., et al. (2021) · Libyan Journal of Medical Sciences · doi:10.4103/ljms.ljms_13_21 · Cited by 1
Statin Intolerance: Diagnosis and Management
Khanna, R., & Himanshu, D. (2017) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0037-1607193
Efficacité et effets indésirables des statines: évidences et polémiques
Michel Komajda, N. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30249-3
Somatosensory amplification, depression, anxiety and pain in statin intolerant patients
Singh, J., Sirna, S. J., Dajani, K. A., Memon, S. B., & Halaris, A. E. (2019) · Cardiovascular Disorders and Medicine · doi:10.15761/cdm.1000194
Vanajakshamma, V., Kasala, L., & Chanda, N. (2019) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0039-1697076
When less is more: dosing simvastatin in decompensated cirrhosis
Simon, T. G. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30321-8
Maidah, N., & Hariani, D. (2021) · LenteraBio Berkala Ilmiah Biologi · doi:10.26740/lenterabio.v11n1.p52-62
Toth, P. P. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_3
Self-citationSelvasudha, N., Koumaravelou, K., & Sridurga Devi, N. (2017) · SM Analytical and Bioanalytical Techniques · doi:10.36876/smabt.1013s
Are Chronic Pain Syndromes the Reason for Statin-Associated Muscle Symptoms?
Sheinin, R., Nogueira, A. R., Bragazzi, N. L., Watad, ., Tiosano, S., Gonen, T., Yavne, Y., Sharif, Κ., Kameri, Y., Amital, D., et al. (2022) · Journal of Family Medicine · doi:10.26420/jfammed.2022.1300
A Pilot Study Suggesting Several Benefits of Alpha Lipoic Acid in Patients with Diabetes
Athyros, V. G., George, S., Koumaras, C., & Athyrou, V. V. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230210100920
Self-citationHíd a szakadék felett : A lipidcsökkentő kezelés ajánlásai és a valósága
Reiber, I., & Mező, I. (2023) · Lege Artis Medicinae · doi:10.33616/lam.33.0364
Kubica, J., Banach, M., Adamski, P., Budaj, A., Buszman, P. P., Somma, S. D., Gabulova, R., Gajda, R., Gurbel, P. A., Kosobucka, A., et al. (2024) · Medical Research Journal · doi:10.5603/mrj.98821
Self-citationStatine: Nebenwirkungen – alternative Therapieoptionen
Makhmudova, U., & Weingärtner, O. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00669-w · Cited by 1
An Investigative Study on Anomaly Detection Techniques Utilizing Interactive Language Models
Satyanarayana, K., & Venkatesh, K. (2025) · Springer proceedings in mathematics & statistics · doi:10.1007/978-3-031-84517-8_29
Samir, A., Mahmoud, K., Ashraf, M., Hossary, H. E. D. G. E., & Taha, H. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00708-1
Predictors of statin intolerance among statin users in primary care using real-world dataPreprint
Rakhshanda, S., Liaw, S., Rhee, J., Rye, K., & Jonnagaddala, J. (2026) · medRxiv · doi:10.64898/2026.02.23.26346866
Rakhshanda, S., Rhee, J., Liaw, S., Rye, K., & Jonnagaddala, J. (2026) · medRxiv · doi:10.64898/2026.02.23.26346865
Heikal, M., Ali, W., Mahdy, M. A., & Gomaa, E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050580
Srivastava, R. A. K. (2026) · Cells · doi:10.3390/cells15171575
Metadata
- Authors
- Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., Greenfield, R. S., Hovingh, G. K., Kostner, K., Serban, C., Lighezan, D., Fras, Z., Moriarty, P. M., Muntner, P., Goudev, A., Ceska, R., Nicholls, S. J., Broncel, M., Nikolic, D., Pella, D., Puri, R., Rysz, J., Wong, N. D., Bajnok, L., Jones, S. R., Ray, K. K., & Mikhailidis, D. P.
- Affiliations
- Medical University of Lodz (PL)
- University of Palermo (IT)
- University of Chicago (US)
- Westchester Medical Center (US)
- University of Belgrade (RS)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Queensland (AU)
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
- University of Ljubljana (SI)
- University of Kansas Medical Center (US)
- University of Alabama (US)
- Queen Giovanna Hospital (BG)
- South Australian Health and Medical Research Institute (AU)
- University of Pavol Jozef Šafárik (SK)
- Indraprastha Apollo Hospitals (IN)
- University of California, Irvine (US)
- Johns Hopkins Medicine (US)
- Imperial College London (GB)
- The Royal Free Hospital (GB)
- ORCID
- Banach, Maciej
- Rizzo, Manfredi
- Toth, Peter P
- Farnier, Michel
- Davidson, Michael H
- Aronow, Wilbert S
- Djuric, Dragan M
- Hovingh, G Kees
- Lighezan, Daniel
- Fras, Zlatko
- Moriarty, Patrick M
- Muntner, Paul
- Goudev, Assen
- Nicholls, Stephen J
- Broncel, Marlena
- Pella, Daniel
- Puri, Raman
- Rysz, Jacek
- Wong, Nathan D
- Jones, Steven R
- Ray, Kausik K
- Mikhailidis, Dimitri P
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2015-04-24
- Volume
- 14
- Issue
- 6
- Pages
- 935-955
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2105307761
- Cited by
- 162
- References
- 205
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 6 · 2023: 13 · 2022: 13 · 2021: 10 · 2020: 14 · 2019: 12 · 2018: 21 · 2017: 25 · 2016: 24 · 2015: 10
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin intolerance, statin-associated muscle symptoms, statin adverse effects, lipid metabolism disorders, cardiovascular disease prevention, statin therapy
- MeSH terms
- Cardiovascular Diseases, Humans, Muscular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
